Annual report
9776.TEDINET S100W42N
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥20.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥19.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥20.1bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥19.1bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥706m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥535m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥708m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥515m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥700m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥598m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥464m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥380m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥569m | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.0bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥794m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥458m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥363m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥16.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥16.7bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥16.5bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥16.1bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥14.5bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥5.1bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥5.5bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥11.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥11.2bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥10.9bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥10.3bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥9.3bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.0bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.9bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.7bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥2.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥731m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.6bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥838m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥395m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥409m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥831m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥3.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥526m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥370m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥348m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥113m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥148.35 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥114.14 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥170.53 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥306.16 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥231.85 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥3,575.27 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,283.71 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,178.25 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥3,016.24 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,708.63 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 67.8% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 64.1% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.2% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.5% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.5% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 10.8% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.0% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 879 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 871 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 938 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 871 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 819 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥17.9bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥17.3bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥17.6bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥17.7bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥16.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥540m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥369m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥719m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥598m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥895m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.6bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.2bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥710m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥681m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥476m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥460m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥472m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.0bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥791m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥15.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥15.1bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥14.5bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥14.4bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥13.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥4.2bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥4.4bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥10.9bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.6bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥10.2bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥9.8bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥9.0bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.0bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥3.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥152.24 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥138.25 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥141.47 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥300.67 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥231.1 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥23 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥23 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥23 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥23 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥23 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥3,484.01 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,194.85 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥3,066.27 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,934.15 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,633.22 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 72.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.7% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 70.5% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.1% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.4% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.4% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.9% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,216,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,216,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 642 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 635 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 627 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 622 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 775 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 87
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥14m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 3 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥175m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥166m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥62m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥125m |
| Clinical Testing Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥279m |
| Clinical Testing Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥298m |
| Clinical Testing Businessreportable segment | employees | at 2025-03-31 | 533 pure |
| Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥7.8bn |
| Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥7.8bn |
| Clinical Testing Businessreportable segment | segment assets | at 2025-03-31 | ¥3.5bn |
| Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥255m |
| Dispensing Pharmacy Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥154m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥115m |
| Dispensing Pharmacy Businessreportable segment | employees | at 2025-03-31 | 303 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.3bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.3bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2025-03-31 | ¥3.4bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥742m |
| Medical Devices Sales And Maintenance Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥3m |
| Medical Devices Sales And Maintenance Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥10m |
| Medical Devices Sales And Maintenance Businessreportable segment | employees | at 2025-03-31 | 19 pure |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥874m |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥719m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment assets | at 2025-03-31 | ¥701m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥4m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥437m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥422m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥20.7bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥20.0bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥719m |
| —segment total | segment assets | at 2025-03-31 | ¥7.5bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥993m |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥450m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥427m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥20.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥20.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥729m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥7.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2023-04-01 → 2024-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2024-03-31 | ¥131m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥126m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2024-03-31 | ¥48m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥90m |
| Clinical Testing Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥124m |
| Clinical Testing Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥284m |
| Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥7.6bn |
| Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥7.6bn |
| Clinical Testing Businessreportable segment | segment assets | at 2024-03-31 | ¥3.5bn |
| Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥109m |
| Dispensing Pharmacy Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥193m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥109m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥11.1bn |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2024-03-31 | ¥3.4bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥733m |
| Medical Devices Sales And Maintenance Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥25m |
| Medical Devices Sales And Maintenance Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥8m |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥937m |
| Medical Devices Sales And Maintenance Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥626m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment assets | at 2024-03-31 | ¥723m |
| Medical Devices Sales And Maintenance Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥9m |
| —segment total | capex | 2023-04-01 → 2024-03-31 | ¥342m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥401m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥20.2bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥19.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥626m |
| —segment total | segment assets | at 2024-03-31 | ¥7.6bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥834m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥346m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥403m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥20.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥19.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥632m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥7.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥924m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2025-03-31 | 3 pure |
| Clinical Testing Businessreportable segment | employees | at 2025-03-31 | 315 pure |
| Dispensing Pharmacy Businessreportable segment | employees | at 2025-03-31 | 303 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,531
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of treasury stock | CurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember | -189975000 | JPY |
| Purchase of treasury stock | CurrentYearDuration_NonConsolidatedMember | -189975000 | JPY |
| Net changes of items other than shareholders equity | CurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember | 18707000 | JPY |
| Net changes of items other than shareholders equity | CurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember | 18707000 | JPY |
| Net changes of items other than shareholders equity | CurrentYearDuration_NonConsolidatedMember | 18707000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_TreasuryStockMember | -189975000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ShareholdersEquityMember | 209773000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember | 18707000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember | 18707000 | JPY |
| Total changes of items during the period | CurrentYearDuration_NonConsolidatedMember | 228480000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_TreasuryStockMember | -948734000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ShareholdersEquityMember | 10764985000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ValuationDifferenceOnAvailableForSaleSecuritiesMember | 104200000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember_ValuationAndTranslationAdjustmentsMember | 104200000 | JPY |
| Net assets | CurrentYearInstant_NonConsolidatedMember | 10869185000 | JPY |
| Directors compensations sga | Prior1YearDuration_NonConsolidatedMember | 109158000 | JPY |
| Directors compensations sga | CurrentYearDuration_NonConsolidatedMember | 118846000 | JPY |
| Salaries allowances and bonuses sga | Prior1YearDuration_NonConsolidatedMember | 2099654000 | JPY |
| Salaries allowances and bonuses sga | CurrentYearDuration_NonConsolidatedMember | 2122742000 | JPY |
| Provision for bonuses sga | Prior1YearDuration_NonConsolidatedMember | 79323000 | JPY |
| Provision for bonuses sga | CurrentYearDuration_NonConsolidatedMember | 76431000 | JPY |
| Provision for directors retirement benefits sga | Prior1YearDuration_NonConsolidatedMember | 8979000 | JPY |
| Provision for directors retirement benefits sga | CurrentYearDuration_NonConsolidatedMember | 9632000 | JPY |
| Legal welfare expenses sga | Prior1YearDuration_NonConsolidatedMember | 358024000 | JPY |
| Legal welfare expenses sga | CurrentYearDuration_NonConsolidatedMember | 359712000 | JPY |
| Rent expenses sga | Prior1YearDuration_NonConsolidatedMember | 43132000 | JPY |
| Rent expenses sga | CurrentYearDuration_NonConsolidatedMember | 45214000 | JPY |
| Rents sga | Prior1YearDuration_NonConsolidatedMember | 314276000 | JPY |
| Rents sga | CurrentYearDuration_NonConsolidatedMember | 308756000 | JPY |
| Supplies expenses sga | Prior1YearDuration_NonConsolidatedMember | 156246000 | JPY |
| Supplies expenses sga | CurrentYearDuration_NonConsolidatedMember | 171713000 | JPY |
| Depreciation sga | Prior1YearDuration_NonConsolidatedMember | 153164000 | JPY |
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 167500000 | JPY |
| Taxes and dues sga | Prior1YearDuration_NonConsolidatedMember | 614558000 | JPY |
| Taxes and dues sga | CurrentYearDuration_NonConsolidatedMember | 618825000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YearDuration_NonConsolidatedMember | 2567000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration_NonConsolidatedMember | 2240000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)北海道財務局長 | |
| Filing date cover page | FilingDateInstant | 2025-06-26 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第61期（自 2024年４月１日 至 2025年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)札幌臨床検査センター株式会社 | |
| Company name in english cover page | FilingDateInstant | SAPPORO CLINICAL LABORATORY INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 伊達 忠應 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北三条西十八丁目２番地２ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | ０１１（６１３）３２１０ | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)総務部長 南 誠 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)札幌市中央区北三条西十八丁目２番地２ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | ０１１（６１３）３２１０ |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |